LOQUINTHA VITAL: Open Payments
NPI 1790989630 · VENTURA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,398 in 14 payments from 8 companies in 2025. Trend: 2023 $1,747 · 2024 $1,130 · 2025 $1,398
Food & beverage: $1,398
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $250 |
| Novo Nordisk Inc | 3 | $247 |
| ABBVIE INC. | 2 | $225 |
| Medtronic, Inc. | 3 | $206 |
| Edwards Lifesciences Corporation | 1 | $154 |
| Abbott Laboratories | 1 | $129 |
| ACADIA Pharmaceuticals Inc | 1 | $121 |
| Amgen Inc. | 1 | $65 |
Products named: MINIMED 780G, SAPIEN 3 Ultra RESILIA, FREESTYLE LIBRE 3, LOKELMA, BREZTRI, Ozempic, NUPLAZID, RINVOQ.
Industry payments across CA — which companies pay providers there.
